Olympiad Research LP Makes New $448,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Olympiad Research LP bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, Holdings Channel.com reports. The firm bought 3,355 shares of the life sciences company’s stock, valued at approximately $448,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. WCM Investment Management LLC boosted its position in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. Geode Capital Management LLC boosted its position in Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after purchasing an additional 48,018 shares during the period. Primecap Management Co. CA boosted its position in Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after purchasing an additional 87,599 shares during the period. Janus Henderson Group PLC boosted its position in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after purchasing an additional 625,245 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after purchasing an additional 54,319 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 3.1 %

ILMN stock opened at $94.20 on Friday. The company has a market capitalization of $14.92 billion, a PE ratio of -12.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a one year low of $93.50 and a one year high of $156.66. The company’s 50 day moving average price is $127.98 and its two-hundred day moving average price is $134.13. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ILMN shares. UBS Group raised their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $130.00 to $100.00 in a research report on Monday, February 10th. Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $159.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.